Equillium Inc (EQ)
NASDAQ:EQ
Want to see EQ full AI Analyst Report?
EQ Stock Chart & Stats
$2.05
-$0.05(-6.85%)
At close: 4:00 PM EST
$2.05
-$0.05(-6.85%)
Day’s Range― - ―
52-Week Range$0.27 - $3.45
Previous CloseN/A
Volume484.47K
Average Volume (3M)883.61K
Market Cap
$196.63M
Enterprise Value$42.38M
Total Cash (Recent Filing)$61.32M
Total Debt (Recent Filing)$692.00K
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Aug 12, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding63,226,555
10 Day Avg. Volume862,141
30 Day Avg. Volume883,611
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)4.98
Price to Sales (P/S)0.00
P/FCF Ratio-6.25
Enterprise Value/Market Cap0.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-536.48
Enterprise Value/Ebitda-2.09
Forecast
1Y Price Target
$7.57Price Target Upside269.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt-to-equity (~0.01) provides durable financial flexibility: the company can fund operations without interest burdens, preserving cash for R&D and allowing future financings to focus on equity or partnerships rather than servicing debt. This reduces bankruptcy risk relative to leveraged peers.
Recent $35M Private PlacementThe $35M private placement with a healthcare specialist investor materially extends development runway for EQ504 and working capital needs. The structure (pre-funded warrant, registration rights) balances investor liquidity and reduces immediate public dilution, lowering near-term funding risk for clinical programs.
Focused Immunomodulatory R&DA concentrated R&D strategy targeting specific immune signaling pathways (e.g., anti-CD6 itolizumab and EQ504) creates a clear scientific focus and potential durable differentiation. Success in niche autoimmune indications can yield high-value partnerships or royalties, aligning capital use with core strengths.
Bears Say
Revenue CollapseNear-zero trailing revenues eliminate internal cash generation and shift the firm's economics to pure R&D spending. Without commercial sales or recurring partner receipts, the company remains binary on clinical success and licensing, increasing long-term financing and execution risk for sustained operations.
Persistent Cash BurnConsistent negative operating and free cash flow (~-$19M TTM) drives ongoing dependence on external financing. Continued burn without revenue forces recurrent capital raises that can dilute equity and redirect management focus from science to financing, constraining long-term strategic optionality.
Capital Structure Dilution RiskBoard-approved reverse-split authority and a doubled authorized share pool materially increase the company's ability to alter outstanding share count or issue equity. While useful for financing flexibility, this creates a persistent dilution risk and potential governance changes that can affect long-term shareholder value and incentive alignment.
Equillium News
EQ FAQ
What was Equillium Inc’s price range in the past 12 months?
Equillium Inc lowest stock price was $0.27 and its highest was $3.45 in the past 12 months.
What is Equillium Inc’s market cap?
Equillium Inc’s market cap is $196.63M.
When is Equillium Inc’s upcoming earnings report date?
Equillium Inc’s upcoming earnings report date is Aug 12, 2026 which is in 67 days.
How were Equillium Inc’s earnings last quarter?
Equillium Inc released its earnings results on May 13, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.046 by -$0.014.
Is Equillium Inc overvalued?
According to Wall Street analysts Equillium Inc’s price is currently Undervalued.
Does Equillium Inc pay dividends?
Equillium Inc does not currently pay dividends.
What is Equillium Inc’s EPS estimate?
Equillium Inc’s EPS estimate is -0.05.
How many shares outstanding does Equillium Inc have?
Equillium Inc has 63,226,555 shares outstanding.
What happened to Equillium Inc’s price movement after its last earnings report?
Equillium Inc reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.046. Following the earnings report the stock price went up 12.121%.
Which hedge fund is a major shareholder of Equillium Inc?
Currently, no hedge funds are holding shares in EQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Equillium Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.57 (269.34% Upside)
$7.57 (269.34% Upside)
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $723.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 15.4%
Last 30 Days ▲ 64.8%
Last 30 Days ▲ 64.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.18%
12-Months-Change
Fundamentals
Return on Equity
-61.43%
Trailing 12-Months
Asset Growth
277.09%
Trailing 12-Months
Company Description
Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
EQ Stock 12 Month Forecast
Average Price Target
$7.57
▲(269.34% Upside)
Technical Analysis
Ownership Overview
13.41% Insiders
3.29% Mutual Funds
38.11% Other Institutional Investors
42.39% Public Companies and
Individual Investors